References
- Gravenstein JS, Smith GM, Sphire RD, et al. Dihydrocodeine. N Engl J Med 1956;254:877-85
- Robertson JR. Dihydrocodeine: second strand of treatment for drug misusers. Drug Alcohol Rev 1996;15:200-1
- Keats AS, Telford J, Kurosu Y. Studies of analgesic drugs: Dihydrocodeine. J Pharmacol Exp Ther 1957;120:354-60
- Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract 2010;64:1681-7
- Leppert W. Dihydrocodeine as an analgesic for the treatment of moderate to severe chronic pain. Curr Drug Metab 2010;11:494-506
- Pedersen L, Borchgrevink PC, Breivik HP, Fredheim OM. A randomized, double–blind, double–dummy comparison of short–and long–acting dihydrocodeine in chronic non–malignant pain. Pain 2014;155:881-8
- Zimmermann M, Arnau H, Hepper M. Pain treatment with dihydrocodeine slow release. Results of a post marketing surveillance study (in German). Schmerz 1995;9:185-97
- Dobrogowski J, Hilgier M. Clinical trial of DHC Continus tablets in the treatment of chronic pain (in Polish). Wspolcz Onkol 2003;7:528-34
- Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence–based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68
- Schmidt H, Vormfelde SV, Walchner–Bonjean M, et al. The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther 2003;41:95-106
- Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31
- Stamer U, Musshoff F, Kobilay M, et al. Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CY2D6 Genotypes. Clin Pharmacol Ther 2007;82:41-7
- Woron J, Grabski B, Siwek M. Pharmacoepidemiological and toxicological aspects of atypical neuroleptics usage (in Polish). Przegl Lek 2011;68:475-9
- Kaye AD, Kaye AM, Urman RD. Essentials of pharmacology for anaesthesia, pain medicine and critical care. Springer, NY; 2015
- Summary of product characteristics. Dihydrokodeina 60 mg, 90 mg, 120 mg (in Polish). Available from: www.urpl.gov.pl/files/DHCConinus_tabl_3dawki.pdf [Last accessed 26 August 2015]
- Steynor M, MacDuff A. Always consider the possibility of opioid induced respiratory depression in patients presenting with hypercapnic respiratory failure who fail to improve as expected with appropriate therapy. Case Rep Crit Care 2015;2015:562319
- Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 2015;151:311-15
- Park GR, Shelly MP, Quinn K, Roberts P. Dihydrocodeine-a reversible cause of renal failure? Eur J Anaesthesiol 1989;6:303-14
- Barnes JM, Goodwin FJ. Dihydrocodeine narcosis in renal failure. BMJ 1983;286:438-9
- Litt ZJ. Drug eruption & reaction manual. CRC Press, Boca Raton; 2015
- Bazire S. Psychotropic drug directory 2014. Lloyd–Reinhold Communications, Dorsington; 2014
- Zamparutti G, Schifano F, Corkery JM, et al. Deaths of opiate/opioid misusers involving dihydrocodeine, UK, 1997–2007. Br J Clin Pharmacol 2011;72:330-7